Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | ATM | Q13315 | 1/20 | 0.61 |
| ▸ | AURKA | O14965 | 12/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | TP53 | P04637 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25432836 | 0.84 | CYP17A1 (0.50) | AURKAKMT2APOLB | |
| SCHEMBL23928676 | 0.83 | AURKA (0.66) | L3MBTL1ATMAURKAMEN1KMT2A | |
| SCHEMBL4296769 | 0.81 | L3MBTL1 (0.46) | L3MBTL1ATMAURKAMEN1KMT2A | |
| SCHEMBL28771391 | 0.78 | ALDH1A1 (0.78) | L3MBTL1ATMAURKAMEN1KMT2A | |
| SCHEMBL4501557 | 0.78 | ALDH1A1 (0.82) | L3MBTL1ATMAURKAMEN1KMT2A | |
| SCHEMBL6683128 | 0.77 | L3MBTL1 (0.73) | L3MBTL1ATMAURKAMEN1KMT2A | |
| SCHEMBL23928522 | 0.76 | MAPT (0.74) | L3MBTL1ATMAURKAMEN1KMT2A | |
| SCHEMBL6681990 | 0.76 | L3MBTL1 (1.00) | L3MBTL1ATMAURKAMEN1KMT2A | |
| SCHEMBL25359886 | 0.75 | CYP17A1 (0.51) | KDM4E | |
| SCHEMBL4502915 | 0.75 | ALDH1A1 (0.74) | L3MBTL1ATMAURKAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548875-B2 | Inhibitor compounds for male contraception | UNIVERSITY OF WASHINGTON (US) | 2023-01-10 | — | — | US | disclosed |
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | UNIVERSITY OF WASHINGTON (US) | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210332030-A1 | INHIBITOR COMPOUNDS FOR MALE CONTRACEPTION | ALDH1A1, ALDH3A1, ALDH16A1 | L3MBTL1 4048/4885ATM 4205/4885AURKA 3852/4885 |
| US-11548875-B2 | Inhibitor compounds for male contraception | ALDH1A1, ALDH3A1, ALDH16A1 | L3MBTL1 4048/4885ATM 4205/4885AURKA 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.